Emyria (ASX:EMD)
Broker Briefing Webinar | Michael Winlo, CEO
only | Emyria develops biopharmaceuticals |
guided by Real-WorldData collected | |
usenal | with patients receiving care at our |
clinics | |
1
Emyria is a biotech that, uniquely:
provides care, generates data & develops treatments
only | Care | ||||||
Patients w | |||||||
unmet needs + | |||||||
new | |||||||
treatments | |||||||
5 clinical sites (Emerald Clinics) treating | ||||
more than 40 complex conditions in | ||||
use | >6,000 patients aged 2-98. | |||
2 | ||||
nal | ||||
Emyria is a biotech that, uniquely:
provides care, generates data & develops treatments
nal use only
5 clinical sites (Emerald Clinics) treating more than 40 complex conditions in >6,000 patients aged 2-98.
Data
Insights from
Real-World
Data (RWD)
One of the largest patient registries of ethically sourced Real-World Data (RWD) on treatment effects of GMP-gradecannabinoids to guide biopharmaceutical development.
3
Emyria is a biotech that, uniquely:
provides care, generates data & develops treatments
nal use only
5 clinical sites (Emerald Clinics) treating more than 40 complex conditions in >6,000 patients aged 2-98.
Data
Insights from
Real-World
Data (RWD)
One of the largest patient registries of ethically sourced Real-World Data (RWD) on treatment effects of GMP-gradecannabinoids to guide biopharmaceutical development.
Treatments
Proprietary
drug design +
global
registration
2 FDA-compliant drug development
programs seeking registration with major global regulators. More in development.
4
Emyria's active clinical development programs
Platform | Active programs | Initial opportunities | ||||||||||
onlyuse | ||||||||||||
Ultra-pure | ||||||||||||
Low-doseCBD for | Over-the-counter treatment | |||||||||||
cannabinoid- | EMD | -RX5 | ||||||||||
for psychological distress | ||||||||||||
based medical | multiple indications | |||||||||||
$200m/yr (Australia alone) | ||||||||||||
treatments | ||||||||||||
(CBMTs) | See ASX Announcement 19 October 2021 | |||||||||||
High-doseCBD for | ||||||||||||
EMD | -RX7 | |||||||||||
multiple indications | ||||||||||||
nal | [1] https://www.coherentmarketinsights.com/market-insight/post-traumatic-stress-disorder-treatment-market-4433 | |||||||||||
Next 3-6 months
- Complete pivotal trials
- TGA registration application
- New formulations
- Launch US registration programs
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Emyria Ltd. published this content on 24 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 March 2022 04:17:03 UTC.